Technical Analysis for GNCA - Genocea Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 0.74 0.00% 0.00
GNCA closed unchanged on Monday, March 18, 2019, on 58 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical GNCA trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Support Bullish 0.00%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 20 DMA Support Bullish 0.00%
Mar 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 15 Spinning Top Other 0.00%
Mar 15 Wide Bands Range Expansion 0.00%
Mar 14 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%

Older signals for GNCA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Biotechnology Medical Specialties Infectious Diseases Immunotherapy Vaccination Microbiology Infections Vaccine Herpes Simplex Herpes Simplex Virus Malaria Sexually Transmitted Diseases And Infections Herpes Simplex Research Viruses
Is GNCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.19
52 Week Low 0.28
Average Volume 404,306
200-Day Moving Average 0.6656
50-Day Moving Average 0.6194
20-Day Moving Average 0.7237
10-Day Moving Average 0.7669
Average True Range 0.0722
ADX 29.76
+DI 20.3249
-DI 13.2528
Chandelier Exit (Long, 3 ATRs ) 0.7284
Chandelier Exit (Short, 3 ATRs ) 0.7049
Upper Bollinger Band 0.9511
Lower Bollinger Band 0.4963
Percent B (%b) 0.54
BandWidth 62.84372
MACD Line 0.0466
MACD Signal Line 0.0556
MACD Histogram -0.0089
Fundamentals Value
Market Cap 21.18 Million
Num Shares 28.6 Million
EPS -2.04
Price-to-Earnings (P/E) Ratio -0.36
Price-to-Sales 0.00
Price-to-Book 1.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.81
Resistance 3 (R3) 0.81 0.79 0.80
Resistance 2 (R2) 0.79 0.77 0.79 0.80
Resistance 1 (R1) 0.76 0.76 0.75 0.76 0.79
Pivot Point 0.74 0.74 0.73 0.74 0.74
Support 1 (S1) 0.71 0.72 0.70 0.72 0.69
Support 2 (S2) 0.69 0.71 0.69 0.68
Support 3 (S3) 0.66 0.69 0.68
Support 4 (S4) 0.67